TrialBlood cancer journal2024

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

Ricardo D Parrondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.